{
    "nctId": "NCT01424865",
    "briefTitle": "Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial",
    "officialTitle": "Evaluation of the Co-Expression of the Cancer Stem Cell Marker ALDH1 and of HER2 as a Predictor of Adjuvant Trastuzumab Response in Breast Cancers of Women in NSABP B31",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1874,
    "primaryOutcomeMeasure": "ALDH1 expression (percentage of stem cells within the tumor) and association with outcomes regardless of HER2 staining",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Tissue samples from patients with node-positive breast cancer whose tumors overexpress HER2\n* Primary tumor samples that are negative for HER2 using classically accepted cutoffs determined in the metastatic setting\n* Treated with adjuvant therapy comprising doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without trastuzumab in the NSABP-B-31 trial\n\nPATIENT CHARACTERISTICS:\n\n* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}